Finerenone and Dasabuvir: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Finerenone
Dasabuvir
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse effects
Interaction Deep Dive
Coadministration of finerenone and a sensitive CYP2C8 substrate may increase the exposure of the substrate, which may increase the risk of adverse reactions related to CYP2C8 substrates for drugs which are sensitive to minimal concentration changes. Finerenone is a weak CYP2C8 inhibitor at 40 mg. Finerenone increases exposure of CYP2C8 substrates at 40 mg dose. Monitor patients more frequently for adverse reactions caused by sensitive CYP2C8 substrates if finerenone 40 mg is coadministered with such substrates. In drug interaction studies, concomitant use of multiple finerenone 40 mg doses once daily with repaglinide (sensitive CYP2C8 substrate) increased the mean AUC and Cmax of repaglinide by 59% and 30%, respectively. There were no clinically significant differences in the pharmacokinetics of repaglinide when used concomitantly with multiple finerenone 20 mg doses once daily1.
Why it happens (mechanism)
Inhibition of CYP2C8-mediated metabolism by finerenone
Literature reports
1 report — tap to read
a) In drug interaction studies, concomitant use of multiple finerenone 40 mg doses once daily with repaglinide (sensitive CYP2C8 substrate) increased the mean AUC and Cmax of repaglinide by 59% and 30%, respectively. There were no clinically significant differences in the pharmacokinetics of repaglinide when used concomitantly with multiple finerenone 20 mg doses once daily 1.
Common questions
Can I take Finerenone and Dasabuvir together?
Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse effects Always confirm with your pharmacist or prescriber before making any change.
How serious is the Finerenone and Dasabuvir interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Finerenone or Dasabuvir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Product Information: KERENDIA(R) oral tablets, finerenone oral tablets. Bayer HealthCare Pharmaceuticals Inc (per FDA), Whippany, NJ, 2025. DailyMed
Keep reading about Finerenone
Keep reading about Dasabuvir
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist